Candida auris: Is It Really a Killer Fungus?

What Is Candida auris?

Candida is a large genus of microorganisms belonging to the fungal kingdom that commonly live on human skin and within the body, typically existing in balance with other microorganisms without causing any harm. When this happens without symptoms, it is referred to as colonization, meaning the organism is present on or in the body of a “carrier” without actually causing disease.

Candida auris is one of the relatively few species within the Candida genus capable of causing actual disease (candidiasis) in humans, in a manner similar to the much better known Candida albicans, which is responsible for common conditions such as vaginal yeast infections or oral thrush (mughetto).

Compared to these more familiar species, Candida auris remains considerably less common. However, what makes it stand out, and what has captured the attention of public health authorities worldwide, is not how frequently it appears, but rather how it behaves once it does.

---

I Just Heard About It on the News, Was It Just Discovered?

Not quite. Candida auris was first formally identified in 2009, although some retrospective reviews suggest that the organism may have actually first been isolated back in 1996 in South Korea, without being recognized as a distinct species at the time. The name “auris” comes from the Latin word for “ear”, chosen because the fungus was first isolated from the ear canal of a patient hospitalized in Japan.

What makes the story of Candida auris particularly fascinating from a scientific standpoint is what happened next. Researchers conducted extensive genetic analyses on strains isolated from different countries around the world, and DNA sequencing revealed something quite unusual: it appears that distinct strains of C. auris emerged independently, in multiple geographic regions, at roughly the same period in time, rather than spreading outward from a single point of origin. This pattern, known as simultaneous independent emergence, is highly unusual for an infectious organism and has led some researchers to propose intriguing, though still largely speculative, hypotheses, including a possible link to climate change, which may have created new environmental pressures allowing this fungus to adapt to survive at human body temperature for the first time.

Despite having been identified over a decade ago, Candida auris has only recently gained widespread media attention, largely due to a growing number of cases being reported globally which understandably raised public concern and curiosity.

---

Is It Really as Dangerous as the Headlines Suggest?

Potentially, yes, it can be genuinely quite dangerous. Candida auris is capable of causing invasive infections throughout the body, meaning it can spread beyond its initial entry point and colonize multiple organs and systems, including the:

• Bloodstream
• Central nervous system
• Kidneys
• Liver
• Bones
• Muscles
• Joints
• Spleen
• Eyes

That said, the most commonly reported sites of Candida auris infection remain the bloodstream, open wounds, and the ear.

The real source of growing global concern, however, is not simply that this fungus can cause invasive disease, since other Candida species can do the same, but rather that Candida auris has repeatedly demonstrated resistance to many, and in some documented cases, ALL of the antifungal medications currently available to treat it.

Given the seriousness of this threat, it is worth looking at exactly how major international health organizations have described it:

• The American CDC (Centers for Disease Control and Prevention) has described it as “a fungus that can cause severe infections and spreads easily between hospitalized patients and nursing home residents… and is often resistant to multiple antifungal drugs”.

• The European Centre for Disease Prevention and Control (ECDC) has emphasized that due to “its propensity to cause outbreaks and its resistance to antifungal drugs, Candida auris represents a risk to patients in healthcare facilities in Europe”.

• The World Health Organization (WHO) includes it among the 19 fungi considered a threat to public health, describing it as a pathogen associated with “high mortality rates”.

Taken together, the reasons behind this heightened level of concern can be summarized as follows:

• It is frequently resistant to the antifungal medications currently available for treatment
• Since its discovery in 2009, it has spread rapidly, and has now been identified in numerous countries across nearly every continent
• It is genuinely difficult to identify using standard laboratory testing methods, meaning it can easily be misidentified as a different, less concerning organism in laboratories that lack specialized equipment or expertise, a problem that can directly lead to inappropriate, ineffective treatment
• It has already caused documented outbreaks within multiple healthcare facilities around the world, which is precisely why rapid identification is so critical, allowing hospitals to implement the necessary infection control precautions before the organism has a chance to spread further
• It can cause severe, invasive infections affecting the entire body, particularly in medically fragile patients, with a fatality rate reported in roughly one out of every three cases of invasive infection

Should I Be Worried About My Health? Can I Get Infected?

No, at present there is essentially no meaningful risk of infection for the general public going about their everyday lives. Candida auris is, for the time being, almost exclusively a concern within hospital and long-term care facility settings, affecting patients who are already significantly medically vulnerable.

That said, this does not mean the situation should be dismissed or ignored. The continued, unchecked spread of drug-resistant strains of this fungus has the very real potential to evolve into a serious and growing public health problem over time, which is precisely why global health authorities are monitoring it so closely and urging healthcare systems to strengthen their infection prevention protocols now, before the situation potentially worsens.

---

How Is It Transmitted?

Candida auris can spread within healthcare facilities through two primary routes: indirect contact with contaminated environmental surfaces or medical equipment, and direct person-to-person transmission.

One particularly concerning characteristic of this fungus, which sets it apart from many other Candida species, is its apparent ability to persist on hospital surfaces, medical equipment, and even skin for extended periods of time, making thorough environmental cleaning and disinfection protocols especially important in preventing its spread within healthcare settings.

Researchers continue to study the precise mechanisms behind its transmission in greater detail, as there remains a great deal to learn about exactly how this organism moves between patients and surfaces within hospital environments.

Who Can Be Infected by Candida auris?

Candida auris remains a relatively rare cause of infection overall, and the patients who do become infected are, in the vast majority of documented cases, already affected by other significant underlying medical conditions, making them considerably more vulnerable to the kinds of infections typically associated with hospital settings.

Based on currently available data, although still considered preliminary, the primary risk factors for Candida auris infection appear to closely overlap with those associated with other types of invasive Candida infections more broadly. These include:

• Recent surgical procedures
• Extended hospital stays (long-term hospitalization)
• Diabetes
• Immunosuppressive therapies, meaning treatments that reduce the strength of the immune system’s natural defenses
• Broad-spectrum antibiotic and antifungal therapy
• The presence of invasive medical devices, such as breathing tubes, central venous catheters, or feeding tubes
• Chronic kidney disease
• HIV infection
• Solid tumors and blood cancers
• A prior history of other types of candidiasis
• Residence in a nursing home or long-term care facility, particularly one that has previously experienced outbreaks

The age range of patients affected to date has been remarkably wide, spanning from premature newborns to elderly adults, underscoring that this is fundamentally a condition tied to underlying vulnerability rather than any specific age group.

---

Is There a Risk of Infection When Traveling to Foreign Countries?

According to the American Society for Microbiology, it is considered unlikely that routine travel to countries where Candida auris infections have been documented would expose a healthy traveler to any meaningful risk of contracting the infection. This is largely because documented infections have occurred almost exclusively among patients who were already hospitalized for other, unrelated medical reasons at the time of exposure, rather than among healthy travelers going about typical tourist or business activities.

In other words, unless you are planning to be hospitalized or to receive extended medical care in a facility with a known active outbreak, international travel alone does not appear to represent a significant source of concern regarding this particular organism.

---

What Are the Symptoms of Candida auris Infection?

The most commonly reported symptoms of invasive Candida infection in general, including that caused by C. auris, are fever and chills that fail to improve despite antibiotic treatment administered for a suspected bacterial infection. This particular clue, persistent fever despite appropriate antibacterial therapy, is often what prompts clinicians to consider a fungal infection in the first place.

Beyond this general presentation, more specific symptoms tend to depend heavily on which part of the body is affected by the infection. For example, in the case of an infected wound, clinicians may observe a worsening of the classic signs of inflammation, including increased redness, swelling, warmth, and the presence of pus or other drainage, despite standard wound care and antibacterial treatment.

As previously mentioned, the most common sites of infection include:

• The ear
• Open wounds
• The bloodstream

It is worth noting that, because these symptoms closely overlap with those of many other, far more common infections, a definitive diagnosis of Candida auris cannot be made based on symptoms alone. Specialized laboratory testing, ideally performed using advanced identification methods such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) or specific molecular testing, is required to accurately confirm the diagnosis and distinguish it from other, more common Candida species.

---

Can It Be Fatal?

Yes, invasive infections caused by any species within the Candida genus have the potential to be fatal, and Candida auris is no exception to this general rule.

That said, the relatively limited amount of data collected so far does not allow researchers to draw firm, definitive conclusions about whether Candida auris carries a meaningfully higher mortality rate compared to other, more established Candida species. Available statistics suggest a fatal outcome in approximately one out of every three cases of invasive infection, but it is critically important to understand the context behind this number: these statistics primarily describe invasive infections occurring in patients who were already severely compromised by other serious underlying medical conditions at the time of infection. This makes it genuinely difficult to clearly disentangle exactly how much the Candida auris infection itself contributed to the eventual outcome, as opposed to the patient’s pre-existing, often critical, underlying illness.

In practical terms, this means that Candida auris should be understood as a serious opportunistic threat, one that takes advantage of an already weakened body, rather than as an aggressive pathogen capable of causing severe illness in otherwise healthy individuals.

---

How Is It Treated?

The majority of Candida auris infections can be successfully treated using a class of antifungal medications known as echinocandins, which work by disrupting the fungal cell wall, effectively weakening and killing the organism. Echinocandins, which include drugs such as caspofungin, micafungin, and anidulafungin, are generally considered the first-line treatment recommended by most current clinical guidelines when Candida auris infection is confirmed or strongly suspected.

However, and this is precisely where the greatest clinical challenge lies, certain strains of Candida auris have demonstrated resistance not just to echinocandins, but to all three of the major classes of antifungal medications currently available, namely echinocandins, azoles (such as fluconazole), and polyenes (such as amphotericin B). Strains resistant to all three drug classes are understandably the most concerning from both a treatment and public health perspective, as they leave clinicians with extremely limited therapeutic options.

In these particularly difficult, multidrug-resistant cases, a more aggressive treatment approach becomes necessary, typically involving the simultaneous administration of high doses of medications from multiple different antifungal drug classes at once, in an effort to overcome the resistance mechanisms the fungus has developed. This combination approach requires careful management by infectious disease specialists and close monitoring for potential side effects, given the higher doses involved.

Researchers around the world are actively working to develop new antifungal medications specifically capable of overcoming this resistance, along with rapid diagnostic tools that can identify resistant strains more quickly, allowing for faster, more targeted treatment decisions.

---

Can I Do Anything to Prevent Its Spread and Reduce My Risk of Infection?

At the present time, the primary responsibility for preventing the spread of this fungus falls on healthcare facilities themselves, which are expected to implement dedicated infection control guidelines specifically designed to identify, isolate, and manage patients colonized or infected with Candida auris.

From an individual, everyday perspective, the general public health recommendations that already apply to preventing the spread of infections more broadly remain entirely valid and relevant here as well:

• Wash your hands frequently, paying particular attention to proper handwashing after visiting a hospital or other healthcare facility
• Avoid the overuse of antibiotics and antifungal medications, taking these medications only when specifically prescribed by a physician, and always completing the full prescribed course when they are genuinely needed

Within hospital settings, patients may be screened for Candida auris colonization upon admission, particularly if they are being transferred from another healthcare facility with a known history of cases, or if they have other recognized risk factors. If a patient is found to be colonized (meaning the fungus is present on their skin without causing active infection), they may be treated with antiseptic cleansing protocols specifically designed to reduce or eliminate the presence of the organism, thereby lowering the risk of it spreading to other patients or contaminating the surrounding environment.

Healthcare facilities may also implement additional measures for colonized or infected patients, including placement in a private room, use of dedicated medical equipment that is not shared with other patients, and requiring healthcare staff to use appropriate personal protective equipment, such as gowns and gloves, when providing care.

---

Why Is Antimicrobial Resistance Such a Big Deal?

The emergence of Candida auris is, in many ways, a striking real-world example of a much larger and increasingly urgent global health challenge: antimicrobial resistance, sometimes abbreviated as AMR. This term describes the growing phenomenon in which bacteria, viruses, fungi, and parasites evolve mechanisms to survive the very medications specifically designed to kill them, rendering previously effective treatments useless over time.

Antimicrobial resistance develops naturally over time through evolutionary pressure, but this process has been dramatically accelerated by decades of antibiotic and antifungal overuse and misuse, both in human medicine and in agricultural settings. Every time an antimicrobial medication is used, whether appropriately or not, it creates selective pressure that favors the survival of naturally resistant organisms, which can then multiply and spread.

The World Health Organization has repeatedly identified antimicrobial resistance as one of the top global public health threats facing humanity, warning that without coordinated, sustained action, we risk entering an era in which common infections that have been easily treatable for decades could once again become life-threatening. Candida auris, with its documented resistance to multiple, and in some cases all, available antifungal drug classes, represents exactly the kind of organism that public health experts have long warned could emerge as a consequence of this broader resistance crisis.

This is precisely why organizations like the CDC, ECDC, and WHO have responded so seriously and swiftly to the emergence of Candida auris, not necessarily because it currently poses a widespread threat to the general public, but because it serves as an important, sobering warning sign of what could lie ahead if global efforts to combat antimicrobial resistance are not significantly strengthened.

---

Frequently Asked Questions

Is Candida auris contagious between healthy people outside of hospitals?

No, there is currently no significant evidence suggesting that Candida auris spreads between healthy individuals in everyday community settings. Nearly all documented cases of transmission have occurred within healthcare facilities, among patients who were already hospitalized or receiving long-term medical care.

Can Candida auris be found on everyday surfaces like doorknobs or public transportation?

While Candida auris is known for its ability to persist on surfaces for extended periods, this characteristic has primarily been documented and studied within healthcare environments, where the organism is actively present due to colonized or infected patients. There is no current evidence indicating that it poses a risk on everyday public surfaces outside of medical settings.

Should I ask my doctor to test me for Candida auris?

For the vast majority of healthy individuals with no recent hospitalization, no significant underlying medical conditions, and no known exposure to a healthcare facility with a documented outbreak, testing for Candida auris is not necessary or recommended. Testing is generally reserved for hospitalized patients with specific risk factors, as determined by their healthcare providers.

How is Candida auris different from a typical yeast infection?

While both are caused by fungi within the Candida genus, a typical yeast infection is usually caused by Candida albicans and generally remains localized to a specific area of the body, such as the vagina or mouth, responding well to standard antifungal treatments. Candida auris, by contrast, is far more likely to cause severe, invasive infections affecting the bloodstream and internal organs, and it frequently shows resistance to the antifungal medications that would normally be effective against more common Candida species.

Are there vaccines available to prevent Candida auris infection?

No, there are currently no vaccines available to prevent Candida auris infection. Prevention efforts instead focus on strict infection control practices within healthcare facilities, along with the responsible, judicious use of antifungal medications to help slow the further development of drug resistance.

What should I do if I’m scheduled for hospitalization and I’m worried about Candida auris?

If you have specific concerns, it is entirely reasonable to ask your healthcare providers about the infection control measures in place at the facility where you will be treated. Hospitals with strong infection prevention programs routinely screen high-risk patients and follow strict protocols designed to prevent the spread of resistant organisms, including Candida auris.

---

Sources and References

• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
• Centers for Disease Control and Prevention (CDC): Candida auris Clinical Overview
• Centers for Disease Control and Prevention (CDC): Candida auris Infection Control Guidance
• European Centre for Disease Prevention and Control (ECDC): Rapid Risk Assessment, Candida auris in Healthcare Settings, Europe
• World Health Organization (WHO): WHO Releases First-Ever List of Health-Threatening Fungi
• World Health Organization (WHO): WHO Fungal Priority Pathogens List
• American Society for Microbiology: Healthy International Travelers Not Likely to Acquire Candida auris
• Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus, PMC
• Candida auris: A Rapidly Emerging Cause of Hospital-Acquired Multidrug-Resistant Fungal Infections Globally, Nature Reviews Microbiology